MKI67 and neoplasm: This strategy should be offered as a valid option in the treatment of advanced/metastatic GEP-NETs in selected patients with high-risk features (Ki67 ≥ 15%; 18-FDG PET/CT scan positive; high tumor burden; clinical impairment).